Reconstruction is not renovation – the role of remodeling in asthma

Markus Weckmann¹
Thomas Trian¹
Brian GG Oliver
Department of Pharmacology,
The University of Sydney, Sydney, Australia; Woolcock Institute of Medical Research, Camperdown, NSW-2050, Australia; Bosch Research Institute, University of Sydney, Sydney, Australia
¹These authors contributed equally

Abstract: The chronicity of asthma results not only in persistent lung inflammation but also in changes in structure and composition of this vital organ. These changes are most commonly referred to as remodeling, and include epithelial dysplasia, angiogenesis, changes in the extracellular matrix and increased smooth muscle mass. In this review we summarize recent findings on the contribution of remodeling to the pathological phenotype of asthma. We discuss how and why current treatment (such as corticosteroids) options fail to adequately treat remodeling.

Keywords: asthma, remodeling, epithelium, vascular, smooth muscle

Asthma
Asthma is a chronic inflammatory disease of the airways, characterized by reversible airflow obstruction. In addition to chronic inflammation, the asthmatic airways have several structural changes, such as increased smooth muscle mass, differences in the extracellular matrix composition, increased vascularity and epithelium dysfunction. Collectively these changes are known as remodeling, and are thought to contribute to the airways’ increased ability to respond to a wide range of stimuli (hyper-responsiveness). Bronchial hyper-responsiveness (BHR) is quantified as the change in lung function, due to airway constriction, invoked by a range of agents. Agents are either non-specific, such as pharmacologically or chemically active molecules, or physical or physiochemical agents. Agents can also be specific, for example allergens. Worldwide the prevalence of asthma is increasing; however it remains to be seen if the increased prevalence observed over the last century continues.¹ ² This may in part be due to better training of the medical community to recognize the symptoms of asthma, and the increase in environmental irritants and allergens such as the house dust mite.

Pathology of asthma
In 1922, a landmark study was carried out by Huber and Koessler on the airways of 21 patients who had died of asthma and seven patients who had died from other causes. The major findings from their report are still relevant today, in that they found that in bronchi with an external diameter of greater than 2 mm, the subepithelial layer, the smooth muscle layer and the total wall thickness were all increased.³ Endobronchial biopsies have confirmed that non fatal asthma is an inflammatory disease.⁴ ⁶ Laitinen and others (1985) carried out a bronchoscopic study of various sites within the lungs of asthmatic subjects, and found that inflammation and tissue destruction were apparent at all sites sampled.⁴ In addition the inflammatory gene expression profile has been shown to be different in asthma using in-situ hybridization,⁵ and furthermore the specific source and expression of various cytokines differs in asthmatic tissue.⁶ Eosinophilia has for many years been considered a distinguishing feature of asthma,
however eosinophilia has also been observed in other airways diseases such as eosinophilic bronchitis. Recently a report by Brightling et al highlighted the possible importance of mast cells located within smooth muscle bundles of subjects with asthma. Mast cell infiltration of the smooth muscle layer was found to be significantly higher in asthmatic subjects when compared to non-asthmatics, and to subjects with eosinophilic bronchitis. However mast cells located in the smooth muscle bundles may not be a distinguishing feature of asthma since this was also found in patients with chronic obstructive pulmonary disease (COPD) and subjects who were currently smoking. The role of the neutrophil in the pathology of asthma has for the most part been overlooked. Analysis of sputum from asthmatics reveals elevated numbers of neutrophils during exacerbation. This may however more likely reflect the immune response to respiratory tract infections and as such may not be a feature of stable asthma. On the other side, neutrophilia is also observed in sudden onset fatal asthma, indicating the role of the neutrophil in more severe manifestations of the disease. A report by Wenzel and co-workers found neutrophilia to be present in severe asthmatics that had been treated for five or more years with high doses of oral steroids, when compared to non-asthmatics and mild asthmatic subjects requiring treatment with inhaled β agonists alone. It is not known if neutrophilia observed in asthma is due to corticosteroid treatment alone, since corticosteroids reduce eosinophil numbers and inhibit neutrophil apoptosis. It is conceivable that the neutrophilia observed in asthma is due to factors other than steroid use or respiratory infection.

**Airway remodeling**

Histological examination has demonstrated that in asthma the airway wall is thickened, due to epithelial dysplasia, angiogenesis, increased extracellular matrix (ECM) deposition, and increased airway smooth muscle (ASM) mass; collectively termed remodeling. Increased mucous and mucous plugs are found in the asthmatic airways. This cannot only physically occlude the airways, but can increase the airway surface tension promoting airway collapse. Aikawa and colleagues (1992) carried out necroscopic morphometric analysis of subjects’ lungs who had died from an asthma attack in comparison to lungs from subjects with asthma who had died of other causes. A 30-fold increase in goblet cells and a three-fold increase in mucous production were observed in fatal asthma. Furthermore the mucin composition of mucous is altered in tissues from patients with fatal status asthmaticus in comparison to milder asthma, with an increase of mucin (MUC) gene 5 subtype AC and MUC5B found on the luminal side of the epithelium. In contrast, these were not present at this location in non-asthmatic tissue.

Remodeling is a consistent feature of both fatal and milder manifestations of asthma. A report by Roche and colleagues described thickening below the basement membrane due to collagen deposition, and not increased basement membrane thickness as previously believed. The increased collagen deposition was not due to epithelial dysfunction, and is most likely due to fibroblast activation. This, as Roche and colleagues pointed out, is more correctly called subepithelial fibrosis. The subepithelial fibrosis is due to deposition of collagens type I, III, and V.

**Smooth muscle cell remodeling**

In 2004, Mitzner asked the question: “Airway smooth muscle: the appendix of the lung”? In this paper, Mitzner postulated that airway smooth muscle is a worthless structure with no essential physiological function that can lead to serious medical problems. Airway smooth muscle is largely involved in the bronchial remodeling that occurs in asthma. Many studies show an increase in airway smooth muscle mass in fatal asthma. Trian et al examined bronchus from severe asthmatics, (GINA 4) using specimens from biopsies, and showed an increase in smooth muscle area compared to non-asthmatics. However, this increase of airway smooth muscle mass has also been shown in non-fatal asthma, ie, mild and moderate. Carroll et al examined bronchial tissue from fatal asthma, those dying of other causes with a history of asthma (mild and moderate asthma) and those who died of other causes without any history of respiratory disease. They found a greater area of smooth muscle in the cartilaginous airways of fatal asthma compared to non-fatal and non-asthmatic. The inner wall area was greater in the fatal and non-fatal cases than in the control cases in the small cartilaginous airways and membranous bronchioles (MB). In small MB (perimeter <2 mm), the total and outer wall areas were greater (p < 0.05) in cases of fatal and non-fatal asthma than in control cases. Remodeling of the smooth muscle layer has a key role as an important effector of the pathology of asthma. For example, there is a correlation between BHR early phase amplitude and smooth muscle mass.

Asthmatic smooth muscle remodeling is also characterized by an increase of extracellular matrix between smooth muscle cells. In a recent study, Begueret et al examined biopsies from severe asthmatics using electron microscopy.
study, the authors found a higher degree of organization of the extracellular matrix between airway smooth muscle cells. However, all these studies need to be viewed cautiously because ASM mass is quite difficult to measure due to problems in obtaining biopsies. Quantification of smooth muscle mass increase in asthma needs the involvement of new technology to assess specifically smooth muscle mass such as quantitative morphometry and/or laser dissection. Due to the difficulty in obtaining and assessing smooth muscle remodeling in asthma using human biopsies, many studies have been done using animal models. Using long-term ovalbumin sensitization models, smooth muscle asthma remodeling can be found, with an increase of the smooth muscle mass. Moreover, McMillan et al found that prolonged allergen challenge using ovalbumin in mice leads to persistent airway remodeling.

**Other changes in smooth muscle layer in asthma**

As mentioned above, asthmatic smooth muscle features an inter-cellular increase of extracellular matrix. This increase of matrix seems to be an important characteristic. In a recent study, Slats found that airway hyperresponsiveness, FEV₁% predicted, and airway responses to deep inspiration are associated with components of the extracellular matrix. In 2004, Johnson et al showed that an external protein matrix could modulate ASM proliferation in asthma. Another recent study using bovine tracheal smooth muscle shows that extracellular matrix proteins differentially regulate both phenotype and function of intact ASM in terms of contraction and proliferation.

According to the literature, the mechanism of smooth muscle remodeling seems to involve both hyperplasia and hypertrophy. Indeed, there are some studies which involve hypertrophy in the increase of airway smooth muscle cell mass in asthma. In a recent study, Trian et al suggested that the increase of smooth muscle cell proliferation in asthma, previously shown by Johnson et al was due to an increase of mitochondrial mass in asthmatic airway smooth muscle. This increase of mitochondrial mass was found only in smooth muscle cells and only in severe asthmatic patients. In this paper, the authors also explained this increase by a deregulation of the mitochondrial biogenesis, with an up-regulation found in asthmatic airway smooth muscle cells. The cause of this activation seems to be a calcium deregulation involving the voltage operated channels (VOCs).

However, in an asthmatic bronchus there are many other factors that can induce smooth muscle cell proliferation (see Table 1). For example, one of the other characteristics of the smooth muscle layer remodeling that occurs in asthma, is the specific infiltration of mast cell. Airway smooth muscle layer mast cells found in asthma are in an activated state, primed to release mediators. One of these mediators, mast cell tryptase has been shown to be an activator of smooth muscle proliferation in vitro. This activation of ASM via the protease activated receptor 2 (PAR-2) is also involved in the secretion of TGF-β1 and stem cell factor (SCF), two mast cell chemotactic factors that induce an activation loop between mast cell and ASM that could be involved in ASM remodeling by induction of smooth muscle cell (SMC) proliferation. Other factors have been shown to induce smooth muscle cell proliferation, for example, platelet derived growth factor (PDGF) or insulin-like growth factors 1 and 2 (IGF-1 and IGF-2). Smooth muscle proliferation is also induced by the interaction and the close relationship between all the cell types in the bronchus. One of the examples is the relationship between mast cells and SMC described above, but there is also a close interaction between epithelial cells and smooth muscle cells. For example, bronchial epithelial cells can release epidermal growth factors which has been shown to have a potential mitogenic activity on bronchial airway smooth muscle cell.

Finally, there is also another hypothesis to explain this increase in SMC mass suggested by Ramos-Barbon who found a decrease in SMC apoptosis in an asthmatic rat model. However, the mechanism of smooth muscle increase in asthma is still controversial. Begueret et al used immunohistochemistry to assess the presence of Ki67 staining in airway smooth muscle cells. In this study, the authors could not find any staining of Ki67. Moreover, many studies involve hypertrophic mechanisms in smooth muscle remodeling in asthma. In 2004 Zheng et al showed that treatment of guinea pig airway explants with cardiotrophin, a member of the IL-6 family induces an increase of size and protein content of airway smooth muscle cells. Furthermore, TGF-β, which is mostly involved in asthma pathophysiology, has been shown to induce hypertrophy and increase in protein synthesis in airway smooth muscle cells. In a recent study, Deng et al suggested that inhibition of the GSK-3β/eIF2B translational control pathway contributes to airway smooth muscle hypertrophy in vitro and in vivo. However, they also demonstrated that TGF-β-induced hypertrophy does not depend on GSK-3β/eIF2B signaling.
The cardinal function of the lung, gas exchange, requires a vast network of blood vessels ranging from macro- to submicro vascular vessels. Another well-appreciated function of this network is the transport of nutrients and the exchange of heat and water. Additionally, the blood vessel system provides extensive tracks for progenitor cells as well as immune cells. Furthermore, active distribution of airborne substances throughout the body has been described (eg, pharmacological agents and antigens). An extensive valve and vascular smooth muscle system allows an active responding vascular system.

The lymphatic system on the other hand is thought to be of a less complex construction than the blood vessels. Simpler valve systems are supported passively by contraction and expansion of skeletal muscle or tissue. It is proposed that this function is maintained through filamentous structures anchored at the adjacent tissue. Through this passive pump mechanism interstitial fluid, containing among others lipids, proteins and cells, is drained away from the tissue. Accumulation of fluid can occur due to vasodilation (eg, caused by histamine) and leakage of blood vessels. To prevent severe edema, this fluid has to be drained away by the lymphatic system which therefore aids the collection of exogenous proteins such as inhaled antigens. In case of inflammation the lymphatic system represents the collecting (afferent) network for dendritic cells (DC) charged with foreign material (antigens) to be presented in the proximal lymph nodes to generate an adaptive immune response. Under healthy conditions accumulation and drainage represent a balanced process.

Impaired growth of lymphatic vessels is reported to support bronchial lymphoedema in a mouse model of chronic lung inflammation (Mycoplasma pulmonis). Due to inflammation severe asthmatics experience mucosal edema, which may lead to further narrowing of the bronchial caliber, subsequently enhancing breathing difficulties. The current understanding of the importance of the lymphatic system in asthma is limited but it has recently gained more scientific interest.

**Table 1 Factors inducing airway smooth muscle cell proliferation**

<table>
<thead>
<tr>
<th>Classification</th>
<th>Products</th>
<th>Origin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Growth factors</td>
<td>βFGF</td>
<td>ECM, Monocyte, SMC</td>
</tr>
<tr>
<td></td>
<td>IGF-1</td>
<td>Epithelial cell, mesenchymal cell, macrophage</td>
</tr>
<tr>
<td></td>
<td>EGF</td>
<td>Epithelial cell</td>
</tr>
<tr>
<td></td>
<td>NGF</td>
<td>Eosinophil, fibroblast, epithelial cell, mast cell</td>
</tr>
<tr>
<td></td>
<td>PDGF</td>
<td>Platelet, monocyte, SMC, epithelial cell</td>
</tr>
<tr>
<td>Inflammatory products</td>
<td>Elastase</td>
<td>Neutrophil</td>
</tr>
<tr>
<td></td>
<td>β-Hexosaminidase</td>
<td>Mast cell</td>
</tr>
<tr>
<td></td>
<td>Thrombin</td>
<td>Platelet</td>
</tr>
<tr>
<td></td>
<td>Thromboxane A2</td>
<td>Platelet</td>
</tr>
<tr>
<td></td>
<td>Histamine</td>
<td>Mast cell</td>
</tr>
<tr>
<td></td>
<td>Neutrophil elastase</td>
<td>Neutrophils</td>
</tr>
<tr>
<td></td>
<td>Bradykinin</td>
<td>Mast cell</td>
</tr>
<tr>
<td></td>
<td>Trypsin</td>
<td>Mast cell</td>
</tr>
<tr>
<td>Cytokines</td>
<td>IGF-1</td>
<td>Platelet, monocyte, SMC, epithelial cell</td>
</tr>
<tr>
<td></td>
<td>IL-1β</td>
<td>Lymphocyte, monocyte, epithelial cell</td>
</tr>
<tr>
<td></td>
<td>IL-6</td>
<td>Lymphocyte, monocyte, SMC, epithelial cell</td>
</tr>
<tr>
<td></td>
<td>TNF-α</td>
<td>Lymphocyte, monocyte, SMC, epithelial cell</td>
</tr>
<tr>
<td></td>
<td>TGF-β1</td>
<td>Lymphocyte, monocyte, SMC, platelet, ECM</td>
</tr>
<tr>
<td>Others</td>
<td>Endothelin-1</td>
<td>Platelet, monocyte, epithelial cell</td>
</tr>
<tr>
<td></td>
<td>S-HT</td>
<td>Platelet</td>
</tr>
<tr>
<td></td>
<td>Substance P</td>
<td>Neuron, epithelial cell</td>
</tr>
<tr>
<td></td>
<td>ATP</td>
<td>Mesenchymal cell</td>
</tr>
<tr>
<td></td>
<td>Fibronectin</td>
<td>Mesenchymal cell</td>
</tr>
<tr>
<td></td>
<td>Collagen I</td>
<td>Mesenchymal cell</td>
</tr>
<tr>
<td></td>
<td>MMP-2</td>
<td>Endothelial cell, macrophage</td>
</tr>
</tbody>
</table>

Abbreviations: SMC, smooth muscle cell; ECM, extracellular matrix.
The chronic inflammation occurring during asthma requires the support of the vascular system. In case of encounters with foreign material, DCs are charged with antigen and proceed to the lymph nodes for presentation. Replenishment with naïve DCs is maintained via the blood vessels. Additionally, to battle pathogenic viruses or bacteria the recruitment of activated leukocytes (neutrophils, eosinophils and macrophages) is achieved via the same gateway.

Resident structural cells such as lung epithelial cells (type I and II pneumocytes), smooth muscle cells and fibroblasts change expression profiles under inflammatory conditions supporting the growth and extension of the vascular system. ASM are able to produce a wide range of both angiogenic and anti-angiogenic factors such as tissue inhibitor of metalloproteinase (TIMP) 1 and 2, thrombopoietin (TPO), fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) (own unpublished data and Figure 1). VEGF has

![Figure 1](https://www.dovepress.com/)

**Figure 1** Secretion of the anti-angiogenic factors into cell culture medium by airway smooth muscle cells: TIMP-1 A), TIMP-2 B) as well as pro-angiogenic factors: VEGF C), TPO D), bFGF E). No statistical differences are observed between asthmatics (A) and non-asthmatics (NA). F) Treatment (+) with 10⁻⁸ M dexamethasone did not change significantly the expression levels of VEGF in ASM (A or NA) after 24 h. n = 4 for all.
been shown in moderate or severe asthmatics to be elevated in sputum and submucosa and so was FGF, leading to a possible extension of the peri-bronchial vascular system. Simcock and colleagues recently demonstrated increased expression of VEGF by asthmatic airway smooth muscle cells which induced tubule formation of endothelial cells. Our findings support this, however as a trend only (Figure 1 D). Furthermore VEGF is a prominent and powerful modulator of endothelial proliferation.

The mechanism of action is through the interaction with αβ3 integrin. αVβ3 integrin, which leads to the inhibition of focal adhesion kinase (FAK), phosphatidylinositol (PI) −3 kinase, protein kinase B (Akt) and mammalian target of rapamycin (mTOR) as well as the prevention of the dissociation of the eukaryotic translation initiation factor 4E/eukaryotic initiation factor 4E-binding protein 1 (eIF4E/4E-BP1) complex, resulting in the inhibition of cap-dependent protein translation in endothelial cells.

Is remodeling important?
Asthma is characterized by reversible airflow obstruction. While airflow obstruction is often variable, it is now thought that it may not be fully reversible in all asthmatic patients due to chronic airway remodeling. Whether remodeling initiates the development of asthma or occurs secondarily is not known. In children with asymptomatic bronchial hyperresponsiveness, longitudinal studies have demonstrated that the subsequent development of asthma is closely associated with the development of remodeling.
these mediators can act via both an autocrine and paracrine mechanism to increase remodeling.

**Therapeutic options for the treatment of remodeling**

Inflammation can to some degree be treated in asthma, however the current therapeutic regimes may not reverse the remodeling process. Short term treatment of asthmatic subjects with steroids (6 weeks) can reduce the thickness of the basement membrane, however long term treatment with steroids (mean 3.1 years) did not reduce the total thickness of the airways when compared to non-steroid treated asthmatics.

Recently leukotriene receptor antagonists have shown some therapeutic potential for the treatment of airway remodeling in asthma. In a murine model of allergic airways disease blockage of the CysLT1 receptor reduced allergen-induced mucus plug formation, smooth muscle hyperplasia, and airway fibrosis (assessed by collagen deposition). Interestingly, leukotriene receptor antagonists have also been shown to inhibit bleomycin-induced lung fibrosis in mice.

Leukotriene receptor antagonists have also been shown to inhibit human lung myofibroblast proliferation ex vivo from patients with fibrotic lung diseases and there is some evidence that allergen-induced myofibroblasts are inhibited in vivo following treatment with leukotriene receptor antagonists in asthmatics. The mechanism of action by which leukotriene receptor antagonists inhibit airway remodeling is still not known, however since CysLTC4 induces the production of TGFβ from epithelial cells presumably inhibition of the leukotriene receptor would result in decreased TGFβ production. However a recent study by Altraja et al suggests that leukotrienes induce the production of ECM proteins directly from epithelial cells adding further weight to the potential for leukotriene receptor antagonists to treat remodeling. Randomized controlled trials in humans examining the effect of leukotriene receptor antagonists upon airway remodeling in asthma have not been done; however a case report by Pifferi et al demonstrated the therapeutic potential of montelukast to reverse airway remodeling in children. We have shown that a phosphodiesterase 4 inhibitor inhibited the deposition of extracellular matrix proteins ex vivo in human bronchus.

There are no therapeutics available to reverse the increased airway smooth muscle that is observed in asthma. One potential reason why corticosteroids do not decrease the amount of airway smooth muscle in asthma was proposed by Roth et al. They demonstrated an abnormality in the corticosteroid receptor cofactor C/EBPα which results in the loss of antiproliferative effect of the corticosteroids on asthmatic smooth muscle cell proliferation.

Recently, however, a new technique has increased interest to find therapeutics against smooth muscle cell remodeling in asthma. Laviolette’s group treated moderate to severe asthmatics using a bronchoscopic procedure, bronchial thermoplasty, to reduce ASM mass. In this study, the authors have shown that the reduction of ASM mass improves asthma control. Indeed, this “treatment” reduced exacerbation frequency, and increased morning peak expiratory flow and symptom scores. This study showed the importance of smooth muscle remodeling in the pathophysiology of asthma. However, there are no therapeutics to specifically treat endogenous causes of ASM remodeling in asthma.

In contrast it may be possible to specifically treat vascular abnormalities in the asthmatic airway. The pro-angiogenic molecule mostly studied in asthma is VEGF and studies indicate its susceptibility to corticosteroid treatment. Chetta and colleagues observed reduction of VEGF after inhalation of high doses of fluticasone in a subgroup of asthmatic patients. Accompanied by the reduction of VEGF, the vascular area was significantly decreased and fewer vessel numbers were found. Structural and non-resident cells are capable of producing VEGF and other pro-angiogenic factors. However, in ASM expression of VEGF appears to be dexamethasone insensitive unless TGF-β is added as a stimulus (regardless of disease state) supporting a direct, but interlinked effect of corticosteroids on the reduction of this factor (own unpublished data, Figure 1D, F). Furthermore collagen IV expression was increased back to normal (baseline levels of sham treated animals) after dexamethasone treatment in an acute mouse model of allergic airway disease, suggesting that corticosteroids not only reduce pro-angiogenic but also increase potential ECM derived anti-angiogenic factors. In humans endostatin (NC domain of collagen XVIII) has been described to be uninfluenced by corticosteroids (beclomethasone dipropionate) treatment, suggesting a shift from a pro-angiogenic towards an anti-angiogenic environment in asthmatics. Long- or short-acting β antagonists studies on vascular remodeling are rare and effects range from reduction of vascular permeability to antiangiogenic properties of salmeterol.

**Conclusion**

Remodeling affects airway function in asthma, and is likely to contribute to the increased rate of lung function decline.
in asthmatics.73 The current therapies used in humans for the treatment of asthma do not fully reverse the remodeling process, and, in fact, the findings of reports of in vivo treatment are conflicting. In vitro, we and others have demonstrated that ECM deposition may in fact be increased by corticosteroids.101 Mechanisms of the remodeling process need to be better understood to allow the development of new therapeutics, which can target this important aspect of airways disease.

Disclosures
The authors have no conflicts of interest to disclose.

References


